JP2020511935A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511935A5
JP2020511935A5 JP2019528111A JP2019528111A JP2020511935A5 JP 2020511935 A5 JP2020511935 A5 JP 2020511935A5 JP 2019528111 A JP2019528111 A JP 2019528111A JP 2019528111 A JP2019528111 A JP 2019528111A JP 2020511935 A5 JP2020511935 A5 JP 2020511935A5
Authority
JP
Japan
Prior art keywords
amino acid
cell
shiga toxin
targeting molecule
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019528111A
Other languages
English (en)
Japanese (ja)
Other versions
JP7075134B2 (ja
JP2020511935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/065074 external-priority patent/WO2018106895A1/en
Publication of JP2020511935A publication Critical patent/JP2020511935A/ja
Publication of JP2020511935A5 publication Critical patent/JP2020511935A5/ja
Priority to JP2022076399A priority Critical patent/JP7370625B2/ja
Application granted granted Critical
Publication of JP7075134B2 publication Critical patent/JP7075134B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019528111A 2016-12-07 2017-12-07 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子 Expired - Fee Related JP7075134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022076399A JP7370625B2 (ja) 2016-12-07 2022-05-06 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662431036P 2016-12-07 2016-12-07
US62/431,036 2016-12-07
PCT/US2017/065074 WO2018106895A1 (en) 2016-12-07 2017-12-07 Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076399A Division JP7370625B2 (ja) 2016-12-07 2022-05-06 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子

Publications (3)

Publication Number Publication Date
JP2020511935A JP2020511935A (ja) 2020-04-23
JP2020511935A5 true JP2020511935A5 (cg-RX-API-DMAC7.html) 2021-01-21
JP7075134B2 JP7075134B2 (ja) 2022-05-25

Family

ID=60888632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019528111A Expired - Fee Related JP7075134B2 (ja) 2016-12-07 2017-12-07 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
JP2022076399A Active JP7370625B2 (ja) 2016-12-07 2022-05-06 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022076399A Active JP7370625B2 (ja) 2016-12-07 2022-05-06 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子

Country Status (10)

Country Link
US (4) US20210008208A1 (cg-RX-API-DMAC7.html)
EP (2) EP3608333A1 (cg-RX-API-DMAC7.html)
JP (2) JP7075134B2 (cg-RX-API-DMAC7.html)
KR (2) KR102580647B1 (cg-RX-API-DMAC7.html)
CN (2) CN110494443B (cg-RX-API-DMAC7.html)
AU (2) AU2017373962B2 (cg-RX-API-DMAC7.html)
CA (1) CA3043333A1 (cg-RX-API-DMAC7.html)
IL (3) IL266583B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019006656A (cg-RX-API-DMAC7.html)
WO (1) WO2018106895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
WO2018151810A1 (en) 2017-02-17 2018-08-23 The Scripps Research Institute Defining rna-small molecule affinity landscapes enables design of a small molecular inhibitor of an oncogenic non-coding rna
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
US12661409B2 (en) 2018-10-10 2026-06-23 University Of Florida Research Foundation, Incorporated Target validation and profiling of the RNA targets of small molecules
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
CN109528663A (zh) * 2018-12-20 2019-03-29 江西润泽药业有限公司 以ngr(no2)为靶向载体的抗癌药物冻干粉剂及其制备方法和应用
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
US11713347B2 (en) 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
WO2021087084A1 (en) 2019-10-29 2021-05-06 The Scripps Research Institute COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS
CA3156248A1 (en) * 2019-10-31 2021-05-06 R.P. Scherer Technologies, Llc ANTI-CD37-MAYTANSINE ANTIBODY CONJUGATES AND METHODS OF USE THEREOF
CN110862459A (zh) * 2019-11-18 2020-03-06 温州医科大学 Hpv16e7亲和体负载颗粒酶b的亲和毒素靶向分子及其用途
JP2023520440A (ja) * 2020-03-30 2023-05-17 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド 構造標的化リガンドによる発がん性マイクロrna17-92クラスターの標的分解
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022117764A1 (en) * 2020-12-02 2022-06-09 Institut Curie FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US20260202426A1 (en) * 2021-06-25 2026-07-16 Jae Won Chang Early diagnosis system utilizing standard deviation and autocorrelation of dynamic fluorescent or x-ray
WO2023278424A1 (en) * 2021-06-28 2023-01-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
WO2024165823A2 (fr) 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
CN120795060B (zh) * 2025-09-05 2025-11-11 国科大杭州高等研究院 一种用于富集巯基肽段的磁珠材料及其制备方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4934761B1 (cg-RX-API-DMAC7.html) 1969-03-10 1974-09-18
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AU657087B2 (en) 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5635384A (en) 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5552144A (en) 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
AU6912294A (en) 1993-05-12 1994-12-12 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2218601A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
CA2265887A1 (en) 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
CA2222993A1 (en) 1998-02-04 1999-08-04 The Ontario Cancer Institute A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000004926A2 (en) 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US7267973B2 (en) 2000-03-22 2007-09-11 Sibtech, Inc. Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003066854A1 (fr) 2002-02-04 2003-08-14 Yoshida, Hideo Agent anticancereux utilisant des variantes de verotoxines
JP4597528B2 (ja) 2002-02-26 2010-12-15 ジェネンコー・インターナショナル・インク 免疫原性が減少したズブチリシン・カールスバーグタンパク質
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-cd74 항체 및 그 이용방법
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
WO2004058158A2 (en) 2002-12-20 2004-07-15 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7834258B2 (en) 2003-06-30 2010-11-16 Mu-Hyeon Choe Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7585942B2 (en) 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
ATE467641T1 (de) 2004-03-26 2010-05-15 Molecular Templates Inc Bibliothek von toxin mutanten und deren verwendung
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
CA2664549A1 (en) 2005-09-26 2007-03-29 University Health Network Library from toxin mutants, and methods of using same
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007071061A1 (en) 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
EP1991565B1 (en) 2006-02-16 2015-01-21 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Shiga toxoid chimeric proteins
US7373982B2 (en) 2006-03-21 2008-05-20 Halliburton Energy Services, Inc. Cements for use across formations containing gas hydrates
JP4954293B2 (ja) 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
EP2684889A3 (en) 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
US9364557B2 (en) 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
DK2197903T3 (en) 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
US20100298238A1 (en) 2007-10-08 2010-11-25 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
US20090148904A1 (en) 2007-11-13 2009-06-11 Mayfield Stephen P Production of cytotoxic antibody-toxin fusion in eukaryotic algae
WO2009078766A1 (en) 2007-12-17 2009-06-25 Telefonaktiebolaget Lm Ericsson (Publ) Multi-antenna receiver interference cancellation method and apparatus
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
CN102159243B (zh) 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
AU2009293640A1 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of 2G12 -derived domain exchanged antibodies
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US9174169B2 (en) 2009-08-14 2015-11-03 Unifrax I Llc Mounting mat for exhaust gas treatment device
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2012101235A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
SG191977A1 (en) 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
US8895006B2 (en) 2011-03-04 2014-11-25 Rutgers, The State University Of New Jersey Ricin ribosome binding protein compositions and methods of use thereof
EP2704739B1 (en) 2011-05-06 2017-07-12 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Recombinant immunotoxin targeting mesothelin
WO2012162418A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
EP2778173A1 (en) 2013-03-15 2014-09-17 Laboratoire Français du Fractionnement et des Biotechnologies Antibody directed against anthrax toxins and its uses
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20220401568A1 (en) 2014-01-27 2022-12-22 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
JP6814634B2 (ja) 2014-02-05 2021-01-20 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法
PT3604333T (pt) 2014-03-11 2021-06-07 Molecular Templates Inc Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
CN106103416B (zh) 2014-03-14 2021-03-02 拉夸里亚创药株式会社 作为trpm8拮抗剂的氮杂螺衍生物
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
CA2951887A1 (en) 2014-06-12 2015-12-17 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
US10550197B2 (en) * 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
CN105713087B (zh) 2014-11-12 2020-05-08 北京康乐卫士生物技术股份有限公司 人乳头瘤病毒58型单克隆抗体及其应用
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
CN109195991B (zh) 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
JP7011657B2 (ja) 2016-10-30 2022-02-10 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗pd-l1抗体および変異型
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
US11597914B2 (en) 2016-12-26 2023-03-07 Dankook University Cheonan Campus Industry Academic Cooperation Foundation IgG type monoclonal antibodies specifically binding to odontoblast surface
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
JP7201599B2 (ja) 2017-02-28 2023-01-10 中外製薬株式会社 プロテインlを用いたタンパク質精製
LT3592769T (lt) 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1
WO2019059400A1 (ja) 2017-09-25 2019-03-28 Jsr株式会社 イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
KR20200143634A (ko) * 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds

Similar Documents

Publication Publication Date Title
Luo et al. Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo
JP6896021B2 (ja) 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素aサブユニット領域とを含む細胞毒性タンパク質
Pounraj et al. Targeting tumor heterogeneity with neoantigen-based cancer vaccines
AU2020203816B2 (en) Coated Oncolytic Adenoviruses for Cancer Vaccines
US12582609B2 (en) Cancer vaccines
JP2024037858A (ja) 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020169177A (ja) ネオエピトープワクチン組成物及びその使用方法
KR20210038886A (ko) 개인화된 암 백신 에피토프 선택
ES2874077T3 (es) Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
JP2020513779A5 (cg-RX-API-DMAC7.html)
Kramer et al. Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity
Mohsen et al. Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
AU2017211387A1 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP2025500373A (ja) Mrna治療用組成物
Li et al. Immunotherapy in colorectal cancer: Statuses and strategies
JP2017509652A (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
Chen et al. mRNA vaccine development and applications: A special focus on tumors
Kang et al. Targeted coating with antigenic peptide renders tumor cells susceptible to CD8+ T cell-mediated killing
Lee et al. Nano-assembly of a chemically tailored Cas9 ribonucleoprotein for in vivo gene editing and cancer immunotherapy
Ramirez et al. Engineering protein nanoparticles functionalized with an immunodominant Coxiella burnetii antigen to generate a Q fever vaccine
Li et al. Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen
Xing et al. Vaccine therapies for glioma: clinical frontiers and potential breakthrough
Xie et al. Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application
US20250049914A1 (en) Steroid acid-peptide based intracellular cargo delivery
JP2009284908A (ja) Cyp1b1核酸および使用の方法